# US 2016/0354326 A1 · Local anesthetic solution for dental and/or contrast media use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354326 A1
- Document ID: US20160354326A1
- Status: Published application
- Kind: A1
- Application number: 15/200,041
- Filed: 2016-07-01
- Published: 2016-12-08
- Earliest claimed: 2014-01-01
- Assignees: Real Time Imaging Technologies, LLC
- Applicants: Real Time Imaging Technologies, LLC
- Inventors: Daniel UZBELGER FELDMAN
- Web page: https://patentgrep.com/patent/US20160354326A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61B 6/032: {Transmission computed tomography [CT]}
- A61B 6/481: {involving the use of contrast agents}
- A61B 6/485: {involving fluorescence X-ray imaging}
- A61B 6/51: for dentistry
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0063: {Periodont}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/381: having five-membered rings
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 49/04: X-ray contrast preparations
- A61M 5/007: {for contrast media}
- A61M 5/14: Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M 5/178: Syringes
- A61M 11/00: Sprayers or atomisers specially adapted for therapeutic purposes (in general B05B; {aerosol containers B65D83/14})
- A61P 23/02: Local anaesthetics
- A61M 2202/048: Anaesthetics
- A61M 2210/0618: Nose
- A61M 2210/0625: Mouth
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An improved local anesthetic solution with diminished bitter taste includes an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant. The bitterness suppressant includes one or more compounds selected from the group consisting of: a sugar selected from the group consisting of monosaccharide sugars, disaccharide sugars, polysaccharide sugars, and combinations of the any of the foregoing; sweet-tasting compounds; acids; amino acids; salts; miscellaneous suppressant substances; and combinations of any of the foregoing. The improved local anesthetic solution optionally includes one or more additional agents selected from the group consisting of: buffering agents; vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.

## Claims

### Claim 1

An improved local anesthetic solution with diminished bitter taste, the solution comprising:
an anesthetic agent;
an anesthetic solution vehicle; and
a bitterness suppressant;
wherein the bitterness suppressant includes one or more compounds selected from the group consisting of:
a sugar selected from the group consisting of: monosaccharide sugars; disaccharide sugars; polysaccharide sugars; and combinations of the any of the foregoing;
sweet-tasting compounds;
acids;
amino acids;
salts;
miscellaneous suppressant substances; and
combinations of any of the foregoing.

### Claim 2 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the anesthetic solution vehicle includes an aqueous form.

### Claim 3 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the anesthetic solution vehicle includes a non-aqueous form.

### Claim 4 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the anesthetic agent is selected from the group consisting of: lidocaine derivates; tetracaine derivates; xylocaine derivates; mepivacaine derivates; prilocaine derivates; bupivacaine derivates; etidocaine derivates; ropivacaine derivates; articaine derivates; and combinations of any of the foregoing.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the sugar is selected from the group consisting of: dextrose; fructose; galactose; glyceraldehydes; lactose; maltose; sucrose; starch; glycogen; and combinations of any of the foregoing.

### Claim 7 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the sugar is present in the solution in amounts ranging from about 0.0001 to about 1,000 milligram per milliliter.

### Claim 8 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the bitterness suppressant includes a sweet compound selected from the group consisting of: stevia; aspartame; sucralose; neotame; acesulfame potassium; saccharin; sodium saccharin; advantame; cyclamates; lyzozyme, alitame; lactisole; corn syrup; high fructose corn syrup; sugar alcohols; thaumatin; glycosides; terpenoid glycosides; polyhydric alcohols; dipeptide derivatives; N-sulfonylamides; sulfamates; proteins; dihydrochalcones; chlorodeoxysugars; polychlorodeoxysugars; monodeoxysugars; polydeoxysugars; and combinations of any of the foregoing.

### Claim 9 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the bitterness suppressant includes an acid selected from the group consisting of: acetic acid; lactic acid; malic acid; citric acid; and combinations of any of the foregoing.

### Claim 10 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the bitterness suppressant includes an amino acid selected from the group consisting of: lysine; glutamic acid; eucine; arginine; alanine; valine; isoleucine; aspartic acid; phenylalanine; glycine; serine; histidine; threonine; ornithine monohydrochloride; proline; methionine; tryptophan; cysteine; taurine; tyrosine; amino sugars; and combinations of any of the foregoing.

### Claim 11 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the bitterness suppressant includes a salt selected from the group consisting of: sodium chloride; potassium chloride; calcium chloride; magnesium chloride; sodium lactate; and combinations of any of the foregoing.

### Claim at position 12

12-14. (canceled)

### Claim 15 (depends on 1)

The improved local anesthetic solution of claim 1, further comprising one or more additional agents selected from the group consisting of: buffering agents; vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.

### Claim at position 14

16-21. (canceled)

### Claim 22 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the solution is contained within an anesthetic vial with a capacity ranging from about 0.3 milliliters to about 5 milliliters.

### Claim 23 (depends on 1)

The improved local anesthetic solution of claim 1, wherein the solution is administered with a dental syringe, a nasal spray, a needle-free injection system, or a hydrogel method.

### Claim at position 17

24-26. (canceled)

### Claim 27

An improved local anesthetic solution with diminished bitter taste, the solution comprising:
an anesthetic agent;
an anesthetic solution vehicle;
a bitterness suppressant; and
a contrast media agent for enabling visualization of the solution using x-ray technology;
wherein the bitterness suppressant includes one or more compounds selected from the group consisting of:
a sugar selected from the group consisting of: monosaccharide sugars; disaccharide sugars; polysaccharide sugars; and combinations of the any of the foregoing;
sweet-tasting compounds;
acids;
amino acids;
salts;
miscellaneous suppressant substances; and
combinations of any of the foregoing.

### Claim 28 (depends on 27)

The improved local anesthetic solution of claim 27, wherein the contrast media agent includes sodium iodide.

### Claim 29

A method of administering an improved local anesthetic solution with diminished bitter taste, the method comprising:
preparing the improved local anesthetic solution by adding an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant to a vial, wherein the bitterness suppressant includes one or more compounds selected from the group consisting of:
a sugar selected from the group consisting of: monosaccharide sugars; disaccharide sugars; polysaccharide sugars; and combinations of the any of the foregoing;
sweet-tasting compounds;
acids;
amino acids;
salts;
miscellaneous suppressant substances; and
combinations of any of the foregoing;
loading the vial into an anesthesia administration device selected from the group consisting of: a dental syringe; a nasal spray; a needle-free injection system; and a hydrogel method; and
administering the device to a circumscribed area for treatment.

### Claim 30 (depends on 29)

The method of claim 29, wherein the improved local anesthetic solution further includes one or more additional agents selected from the group consisting of: buffering agents;
vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.

### Claim 31 (depends on 29)

The method of claim 29, wherein the circumscribed area includes a patient's nose, or a patient's oral cavity accessed through nerve block or infiltration techniques.

### Claim 32

(canceled)

### Claim 33 (depends on 29)

The method of claim 29, wherein the improved anesthetic solution is applied through a dental syringe having a needle into a location selected from the group consisting of: the root canal system within a tooth; tooth surfaces for caries detection; tooth surfaces for crack and tooth fractures evaluation; periodontal sulcus for pocket measurement assessment; and dental implant templates.

### Claim at position 25

34-35. (canceled)

### Claim 36 (depends on 29)

The method of claim 29, further comprising obtaining an x-ray image after said administering the anesthesia administration device, wherein the step of obtaining the x-ray image includes use of a technique selected from the group consisting of: periapical film and digital dental imaging; low-dose dental imaging; dental fluoroscopy; panoramic imaging; cephalometric imaging; and CBCT scan; and wherein the improved anesthetic solution includes a contrast media agent selected from the group consisting of: silver-based agents; barium-based agents; ionic iodine; non-ionic iodine; sodium iodide, sodium iothalamate, amino sugar derivates; amino sugar derivates combined with iodinated compounds; gadolinium-based agents; iron; iron oxide; iron platinum; manganese; perflubron; nitrogen; perfluorocarbon; protein-based and pharmaceutical prepared microbubble contrast media; and combinations of any of the foregoing.
